NCT00635024 · ADVERSE EVENTS

Adverse events

Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma · Source last updated 2017-02-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: Not reported
Other-event reporting threshold: 0%

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Anti-thymocyte Globulin/Melphalan Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m\^2)	0 / 1	1 / 1	Not reported / Not reported

Group identifiers: EG000: Anti-thymocyte Globulin/Melphalan

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 10.0
stats
group Id
EG000
num Affected
1
num At Risk
1
num Events
1
term
Anemia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Immune system disorders
source Vocabulary
MedDRA 10.0
stats
group Id
EG000
num Affected
1
num At Risk
1
num Events
1
term
Hypersensitivity
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Infections and infestations
source Vocabulary
MedDRA 10.0
stats
group Id
EG000
num Affected
1
num At Risk
1
num Events
1
term
Opportunistic Infection
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Investigations
source Vocabulary
MedDRA 10.0
stats
group Id
EG000
num Affected
1
num At Risk
1
num Events
1
term
Leukopenia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Investigations
source Vocabulary
MedDRA 10.0
stats
group Id
EG000
num Affected
1
num At Risk
1
num Events
1
term
Neutrophil Count Decreased
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Investigations
source Vocabulary
MedDRA 10.0
stats
group Id
EG000
num Affected
1
num At Risk
1
num Events
2
term
Platelet Count Decreased

Complete source fields

event Groups

description
Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m\^2)
id
EG000
other Num Affected
1
other Num At Risk
1
serious Num Affected
0
serious Num At Risk
1
title
Anti-thymocyte Globulin/Melphalan

frequency Threshold

other Events

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA 10.0
stats
group Id
EG000
num Affected
1
num At Risk
1
num Events
1
term
Anemia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Immune system disorders
source Vocabulary
MedDRA 10.0
stats
group Id
EG000
num Affected
1
num At Risk
1
num Events
1
term
Hypersensitivity
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Infections and infestations
source Vocabulary
MedDRA 10.0
stats
group Id
EG000
num Affected
1
num At Risk
1
num Events
1
term
Opportunistic Infection
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Investigations
source Vocabulary
MedDRA 10.0
stats
group Id
EG000
num Affected
1
num At Risk
1
num Events
1
term
Leukopenia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Investigations
source Vocabulary
MedDRA 10.0
stats
group Id
EG000
num Affected
1
num At Risk
1
num Events
1
term
Neutrophil Count Decreased
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Investigations
source Vocabulary
MedDRA 10.0
stats
group Id
EG000
num Affected
1
num At Risk
1
num Events
2
term
Platelet Count Decreased

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice